5.94
前日終値:
$5.55
開ける:
$5.56
24時間の取引高:
353.42K
Relative Volume:
0.37
時価総額:
$297.59M
収益:
$124.00K
当期純損益:
$-49.99M
株価収益率:
-3.5148
EPS:
-1.69
ネットキャッシュフロー:
$-31.03M
1週間 パフォーマンス:
+9.23%
1か月 パフォーマンス:
+29.70%
6か月 パフォーマンス:
+15.82%
1年 パフォーマンス:
-16.39%
Candel Therapeutics Inc Stock (CADL) Company Profile
CADL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CADL
Candel Therapeutics Inc
|
5.94 | 293.10M | 124.00K | -49.99M | -31.03M | -1.69 |
![]()
ONC
Beone Medicines Ltd Adr
|
256.46 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
447.90 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
83.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
499.27 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-20 | 開始されました | Citigroup | Buy |
2025-02-19 | 開始されました | Canaccord Genuity | Buy |
2025-02-07 | 開始されました | BofA Securities | Buy |
2022-12-02 | 開始されました | H.C. Wainwright | Buy |
2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
2021-08-23 | 開始されました | Credit Suisse | Outperform |
2021-08-23 | 開始されました | Jefferies | Buy |
2021-08-23 | 開始されました | UBS | Buy |
すべてを表示
Candel Therapeutics Inc (CADL) 最新ニュース
CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL Stock News - GuruFocus
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - Yahoo Finance
Deutsche Bank AG Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer - MSN
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise
Candel Therapeutics (CADL) Gains on FDA RMAT Designation for CAN-2409 - GuruFocus
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy By Investing.com - Investing.com South Africa
(CADL) Trading Report - news.stocktradersdaily.com
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy By Stocktwits - Investing.com India
Small cap wrap: Midnight Sun Mining, MustGrow Biologics, Candel Therapeutics, HIVE... - Proactive financial news
Market movers: GameStop, Okta, Abercrombie, Candel Therapeutics... - Proactive financial news
Candel Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Prostate Cancer Drug - marketscreener.com
Candel stock gains after FDA RMT designation (CADL:NASDAQ) - Seeking Alpha
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy - MSN
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On? - Benzinga
Candel Therapeutics get FDA’s RMAT designation for prostate cancer therapy - Proactive financial news
Candel Therapeutics (CADL) Receives RMAT Designation for CAN-2409 in Prostate Cancer | CADL Stock News - GuruFocus
Candel Therapeutics Receives FDA RMAT Designation for CAN-2409 - TipRanks
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy - Investing.com
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer - The Manila Times
Candel Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire
Breakthrough: FDA Fast-Tracks Revolutionary Prostate Cancer Therapy Showing 80% Complete Response Rate - Stock Titan
Northern Trust Corp Purchases 6,250 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results fo - GuruFocus
Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results for Prostate Cancer | CADL Stock News - GuruFocus
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation - The Manila Times
Candel Therapeutics to Host Investor Conference Call - GlobeNewswire
Candel Therapeutics to host June 3 call on positive Phase 3 results for prostate cancer therapy - Proactive financial news
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN
Candel Therapeutics: CAN-2409’s Promising Progress Deserves An Upgrade (NASDAQ:CADL) - Seeking Alpha
Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 - MSN
Candel Therapeutics (NASDAQ:CADL) Upgraded at Wall Street Zen - Defense World
Small cap wrap: Excellon Resources, Candel Therapeutics, Forte Minerals... - Proactive financial news
Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025 - Proactive financial news
Candel Therapeutics Unveils Promising Phase 3 Trial Results - TipRanks
Candel Therapeutics to Present Positive Phase 3 Clinical Trial Results of CAN-2409 for Prostate Cancer at ASCO 2025 - Nasdaq
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - GlobeNewswire
Breakthrough Phase 3 Results: First Successful Prostate Cancer Trial in 20 Years Shows 30% Lower Recurrence Risk - Stock Titan
Best Momentum Stocks to Buy for May 19th - The Globe and Mail
New Strong Buy Stocks for May 19th - The Globe and Mail
CADL To Present Prostate Cancer Trial Data, RMD's Q3 Revenue Climbs 8%, AUNA On Watch... - RTTNews
Promising Pipeline Developments and Strong Data Support Buy Rating for Candel Therapeutics - TipRanks
Small cap wrap: Candel Therapeutics, Nevis Brands, Fineqia, Voyageur Pharmaceuticals, atai... - Proactive financial news
Candel Therapeutics Reports Strong Q1 2025 Results - TipRanks
CADL's Cash Reserves Projected to Last Until Early 2027 | CADL S - GuruFocus
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish - NewsBreak: Local News & Alerts
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish By Stocktwits - Investing.com India
Candel Therapeutics (CADL) Reports Q1 Earnings and Cash Reserves - GuruFocus
Market movers: Coinbase, Hertz, Candel Therapeutics, JD Sports... - Proactive Investors
Cardell Flat on Q1 - Baystreet.ca
Candel Therapeutics Inc (CADL) 財務データ
収益
当期純利益
現金流量
EPS
Candel Therapeutics Inc (CADL) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Nichols William Garrett | Chief Medical Officer |
Mar 18 '25 |
Sale |
8.76 |
45,316 |
396,995 |
52,493 |
Barone Francesca | Chief Scientific Officer |
Mar 18 '25 |
Option Exercise |
1.55 |
18,000 |
27,900 |
128,673 |
Barone Francesca | Chief Scientific Officer |
Mar 18 '25 |
Sale |
8.76 |
32,146 |
281,673 |
96,527 |
Tak Paul Peter | Chief Executive Officer |
Mar 18 '25 |
Sale |
8.77 |
25,772 |
226,023 |
226,140 |
Tak Paul Peter | Chief Executive Officer |
Mar 19 '25 |
Sale |
9.00 |
400 |
3,601 |
225,740 |
Tyagarajan Seshu | Chief Technology Officer |
Mar 17 '25 |
Sale |
8.82 |
31,278 |
275,947 |
85,512 |
Schoch Charles | See Remarks |
Mar 17 '25 |
Sale |
8.83 |
5,000 |
44,169 |
38,038 |
大文字化:
|
ボリューム (24 時間):